The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding

Renal Failure

Volumn 34, Issue 3, 2012, Pages 279-285

  Baek, Na Na ^a   Jang, Hye Ryoun ^a   Huh, Wooseong ^a   Kim, Yoon Goo ^a   Kim, Dae Joong ^a   Oh, Ha Young ^a   Lee, Jung Eun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Acute kidney injury; Anticoagulation; Continuous renal replacement therapy; Nafamostat

Indexed keywords

ANTICOAGULANT AGENT; NAFAMSTAT MESILATE;

ACUTE KIDNEY FAILURE; ADULT; AGRANULOCYTOSIS; ANAPHYLAXIS; ANTICOAGULATION; ARTICLE; BLEEDING; CONTINUOUS INFUSION; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DIALYSATE; DIALYSIS; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; FILTER; FLOW RATE; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ANTICOAGULANTS; FEMALE; FIBRINOLYSIN; FOLLOW-UP STUDIES; GUANIDINES; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PROGNOSIS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; SERINE PROTEINASE INHIBITORS; THROMBOSIS;

EID: 84863239727     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.647293     Document Type: Article

References (25)

1. Schetz M, Lauwers PM, Ferdinande P. Extracorporeal treatment of acute renal failure in the intensive care unit: A critical view. Intensive Care Med. 1989;15(6):349-357. (Pubitemid 19236050)
2. Webb AR, Mythen MG, Jacobson D, Mackie IJ. Maintaining blood flow in the extracorporeal circuit: Hemostasis and anticoagulation. Intensive Care Med. 1995;21(1):84-93.
3. van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: The struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol. 1996;7(1):145-150. (Pubitemid 26067101)
4. Morabito S, Guzzo I, Solazzo A, Muzi L, Luciani R, Pierucci A. Continuous renal replacement therapies: Anticoagulation in the critically ill at high risk of bleeding. J Nephrol. 2003;16(4):566-571. (Pubitemid 38120467)
5. Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med. 2000;26(11):1652-1657.
6. Aoyama T, Ino Y, Ozeki M, et al. Pharmacological studies of FUT-175, nafamstat mesylate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol. 1984;35(3):203-227. (Pubitemid 14124814)
7. Ohtake Y, Hirasawa H, Sugai T, et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol. 1991;93:215-217.
8. Nakae H, Tajimi K. Pharmacokinetics of nafamostat mesylate during continuous hemodiafiltration with a polyacrylonitrile membrane. Ther Apher Dial. 2003;7(5):483-485. (Pubitemid 37370008)
9. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsisrelated Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of theWorking Group on Sepsis- Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-710.
10. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31(4):1250- 1256.
11. Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int. 1999;55(5):1991-1997. (Pubitemid 29197989)
12. Okada H, Suzuki H, Deguchi N, Saruta T. Agranulocytosis in a hemodialysed patient induced by a proteinase inhibitor, nafamostate mesylate. Nephrol Dial Transplant. 1992;7(9):980.
13. Ookawara S, Tabei K, Sakurai T, Sakairi Y, Furuya H, Asano Y. Additional mechanisms of nafamostat mesylate-associated hyperkalaemia. Eur J Clin Pharmacol. 1996;51(2):149-151. (Pubitemid 26342771)
14. Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by nafamostat mesylate. Gen Pharmacol. 1995;26(8):1627-1632. (Pubitemid 26033838)
15. Higuchi N, Yamazaki H, Kikuchi H, Gejyo F. Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesylate, following nine administrations in a hemodialysis patient. Nephron. 2000;86(3):400-401.
16. Pedrini LA, De Cristofaro V, Pagliari B, Sama F. Mixed predilution and postdilution online hemodiafiltration compared with the traditional infusion modes. Kidney Int. 2000;58(5):2155-2165.
17. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Inhibition of tissue factor-factor VIIa by nafamostat mesylate: A reply to the rebuttal. Thromb Res. 1995;77(4):381-382.
18. Tolwani AJ, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial. 2009;22(2):141-145.
19. Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal replacement therapy: A worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med. 2007;33(9): 1563-1570. (Pubitemid 47312485)
20. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: A prospective randomized study. Intensive Care Med. 2004;30(2):260-265. (Pubitemid 38253417)
21. Bagshaw SM, Laupland KB, Boiteau PJ, Godinez-Luna T. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care. 2005;20(2):155-161. (Pubitemid 41219636)
22. Evenepoel P, Maes B, Vanwalleghem J, Kuypers D, Messiaen T, Vanrenterghem Y. Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate. Am J Kidney Dis. 2002;39(2):315-323. (Pubitemid 34174254)
23. Gupta M, Wadhwa NK, Bukovsky R. Regional citrate anticoagulation for continuous venovenous hemodiafiltration using calcium-containing dialysate. Am J Kidney Dis. 2004;43(1): 67-73. (Pubitemid 38049437)
24. Cubattoli L, Teruzzi M, Cormio M, Lampati L, Pesenti A. Citrate anticoagulation during CVVH in high risk bleeding patients. Int J Artif Organs. 2007;30(3):244-252. (Pubitemid 46739052)
25. Kutsogiannis DJ, Mayers I, Chin WD, Gibney RT. Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis. 2000;35(5):802-811. (Pubitemid 30238190)